Exploring blood flow and nerve health in glaucoma patients and healthy individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This investigation focuses on understanding neurovascular coupling in patients with glaucoma and healthy subjects. It aims to explore how blood flow in the retina is regulated and its relationship with retinal ganglion cell health, which is crucial for vision. The study employs advanced imaging techniques such as Fourier Domain Doppler Optical Coherence Tomography and Pattern Electroretinography to assess these parameters. By examining both glaucoma patients and healthy controls, the study seeks to identify potential neuroprotective strategies that could benefit those with glaucoma.

Why it matters

Who can join: the full rules

Inclusion criteria

Patients with primary open angle glaucoma

* Diagnosis of manifest primary open angle glaucoma defined as pathological optic disc appearance
* Glaucoma hemifield test outside normal limits
* Untreated IOP ≥ 21 mmHg on at least three measurements in the medical history
* Mean deviation in the visual field test is less than or equal 10dB (for one group) OR more than 10dB (for the other group)

Patients with normal tension glaucoma

* Diagnosis of manifest normal tension glaucoma defined as pathological optic disc appearance
* Glaucoma hemifield test outside normal limits
* No evidence of untreated IOP \> 20 mmHg in the medical history
* Mean deviation in the visual field is less than or equal 10dB (for one group) OR more than 10dB (for the other group)

Patients with ocular hypertension

* Normal ophthalmic findings except presence of ocular hypertension defined as untreated IOP ≥ 21 mmHg on at least three measurements in the medical history
* No signs of glaucomatous damage in the optic disc
* or the glaucoma hemifield test

Healthy control subjects

* Normal ophthalmic findings
* IOP \< 20 mmHg on least three measurements
* No evidence of increased IOP in the medical history
* No signs of glaucomatous damage in the optic disc
* or the glaucoma hemifield test

Exclusion criteria

* History of a severe medical condition as judged by the clinical investigator
* Abuse of alcoholic beverages
* Smoker
* Participation in a clinical trial in the 3 weeks preceding the study
* Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure
* Intraocular surgery within the last 6 months
* Ocular inflammation or infection within the last 3 months
* History of epilepsia
* Diabetes mellitus
* Untreated hypertension with systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 95 mmHg
* Pregnancy
* Planned pregnancy or lactating

Where it's running

• Department of Clinical Pharmacology, Medical University of Vienna
  Vienna, Austria Recruiting

Study contacts

• Principal investigator: Gerhard Garhöfer, MD — Department of Clinical Pharmacology, Medical University of Vienna
• Study coordinator: Gerhard Garhöfer, MD
• Email: gerhard.garhoefer@meduniwien.ac.at
• Phone: 004314040029810

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two eye drops for treating glaucoma and ocular hypertension

  This study is testing if a new eye drop is just as effective as a standard one for treating glaucoma and high eye pressure in people who have these conditions.

  Recruiting at 8 sites Phase 3 Amneal Pharmaceuticals, LLC · Newport Beach, California and 8 other locations · NCT05401357

• TFC-003: a new eye drop combo for open-angle glaucoma and ocular hypertension

  This study tests whether TFC-003, alone or in slight revisions, can safely lower eye pressure in adults with open-angle glaucoma or ocular hypertension who aren’t yet at their target pressure.

  Recruiting Phase 3 Kukje Pharma · Seongnam · NCT07662759

• Imaging the effect of Netarsudil on the eye’s drainage system in glaucoma and ocular hypertension

  This study tests whether netarsudil eye drops change the trabecular meshwork’s structure compared with placebo in adults with ocular hypertension or open-angle glaucoma.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07588152

• Direct Selective Laser Trabeculoplasty to reduce glaucoma medications

  This study will try Direct Selective Laser Trabeculoplasty (DSLT) to reduce the number of eye-drop medications in adults with medically controlled primary open-angle glaucoma or ocular hypertension.

  Recruiting The Eye Institute of West Florida · Largo, Florida · NCT07390890

• HUC3-637 for primary open-angle glaucoma and ocular hypertension

  This study tests whether HUC3-637 is safe and can lower eye pressure in adults with primary open-angle glaucoma or ocular hypertension.

  Recruiting Phase 3 Huons Co., Ltd. · Seoul · NCT07335211

• Rocklatan versus latanoprost for 24-hour eye pressure control in open-angle glaucoma and ocular hypertension

  This trial tests whether a combination eye drop (Rocklatan) lowers eye pressure over 24 hours more than latanoprost alone in adults with open-angle glaucoma or ocular hypertension.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT07325240

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.